PCBL Chemical
PCBL Chemical Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
PCBL expects significant growth in both volume and value over the next 1-2 years, driven by increasing Indian demand and expansion in the U.S. PCBL expects significant growth in both volume and value for the carbon black business over the next 1-2 years, driven by rising domestic demand and international expansion in the U.S.
From PCBL Chemical's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- PCBL expects significant growth in both volume and value over the next 1-2 years, driven by increasing Indian demand and expansion in the U.S. and Europe markets.
- Strong growth in specialty carbon blacks, with new product launches enhancing the portfolio.
- Despite short-term volume timing issues, full-year high single-digit volume growth is anticipated.
- Aquapharm Chemicals aims for revenue and margin growth through launching commercial phosphonates products, expanding green chelates, and geographic penetration in Europe and Latin America.
- Oil and gas segment is expected to be volatile short-term but stabilize later, supporting growth.
- Domestic carbon black sales grew 15% YoY while international volumes are expected to scale up as export logistics normalize.
2 more points management made on revenue & sales performance
Profitability & Margins
See what PCBL Chemical said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY27 greenfield expansion capex will be limited, with major expenses expected next year (refer to Andhra facility licensing progress).
- Around INR100 crores of strategic capex planned in FY27, mainly efficiency and cost optimization projects.
- Overall FY27 capex outlook: ~INR300 crores, plus/minus INR50 crores, mostly maintenance and productivity enhancements; greenfield expansion largely completed.
- Coal tar distillation project progressing well; business plan and equipment evaluation underway with capex approval targeted within the quarter.
- Focus on volume and value growth in carbon black, specialty chemicals, and new product developments driving future investments.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what PCBL Chemical said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
PCBL Chemical — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.1K Cr, net profit ₹40 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What PCBL Chemical's management said in earlier quarters
Frequently Asked Questions
What were PCBL Chemical Q1 FY27 results?
PCBL expects significant growth in both volume and value over the next 1-2 years, driven by increasing Indian demand and expansion in the U.S. PCBL expects significant growth in both volume and value for the carbon black business over the next 1-2 years, driven by rising domestic demand and international expansion in the U.S.
What is PCBL Chemical share price analysis?
PCBL Chemical currently shows a below-average growth signal. The stock trades at a P/E of 47.2 with a market cap of ₹12,494 Cr. Investors should review the full earnings analysis for detailed insights.
Is PCBL Chemical planning capital expenditure?
FY27 greenfield expansion capex will be limited, with major expenses expected next year (refer to Andhra facility licensing progress).
Keep PCBL Chemical on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.